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Abstract
Introduction
Low-density lipoprotein (LDL) cholesterol is a major 
contributor to coronary heart disease and the primary tar-
get of cholesterol-lowering therapy. Substantial disparities 
in cholesterol control exist nationally, but it is unclear how 
these patterns vary locally.
Methods
We estimated the prevalence, awareness, treatment, 
and control of high LDL cholesterol using data from a 
unique local survey of New York City’s diverse population. 
The New York City Health and Nutrition Examination 
Survey 2004 was administered to a probability sample of 
New York City adults. The National Health and Nutrition 
Examination Survey 2003-2004 was used for comparison. 
High LDL cholesterol and coronary heart disease risk were 
defined using National Cholesterol Education Program 
Adult Treatment Panel III (ATP III) guidelines.
Results
Mean LDL cholesterol levels in New York City and 
nationally were similar. In New York City, 28% of adults 
had high LDL cholesterol, 71% of whom were aware of 
their condition. Most aware adults reported modifying 
their diet or activity level (88%), 64% took medication, and 
44% had their condition under control. More aware adults 
in the low ATP III risk group than those in higher risk 
groups had controlled LDL cholesterol (71% vs 33%-42%); 
more whites than blacks and Hispanics had controlled 
LDL cholesterol (53% vs 31% and 32%, respectively).
Conclusions
High prevalence of high LDL cholesterol and inadequate 
treatment and control contribute to preventable illness and 
death, especially among those at highest risk. Population 
approaches — such as making the food environment more 
heart-healthy — and aggressive clinical management of 
cholesterol levels are needed.
Introduction
Coronary heart disease (CHD) is the leading cause 
of death in the United States, accounting for 27% of all 
deaths in 2005 (1). An established body of evidence points 
to reducing low-density lipoprotein (LDL) cholesterol as 
one of the most effective ways to prevent and treat CHD, 
regardless of a person’s risk (2-4). On average, every 1% 
reduction in LDL cholesterol is matched by a 1% reduction 
in the likelihood of a major cardiac event (5). Thus, small 
reductions in population LDL cholesterol could prevent 
many CHD-related deaths.
Despite advances in lowering total blood cholesterol, par-
ticularly throughout the 1980s (6,7), and the recent broad-
scale use of medications targeting LDL cholesterol, control 
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of lipid levels remains poor in the United States. Prevalence 
of high total cholesterol and high LDL cholesterol remained 
virtually unchanged between 1988-1994 and 1999-2004 
(8,9), and only one-fourth of US adults with elevated LDL 
cholesterol have their condition appropriately controlled (8). 
Blacks and Mexican Americans are less likely than whites 
to take drugs from the statin class, and they have poorer 
control (8,10). National estimates of high LDL cholesterol 
are not available for other Hispanics or for Asians.
Local monitoring of the prevalence, treatment, and 
control of CHD risk factors is needed for planning and 
evaluating interventions to prevent disease. Previous 
studies suggest that New York City is similar to or better 
than the rest of the country in terms of prevalence and 
management of some CHD risk factors (hypertension and 
obesity) (11,12) but worse for others (diabetes) (12,13). 
However, no study has examined LDL cholesterol levels 
by using a representative sample in New York City or in 
any exclusively urban setting. In this study, we examine 
prevalence, awareness, treatment, and control of high 
LDL cholesterol in New York City adults by using the first 
community Health and Nutrition Examination Survey 
(NYC HANES). To define high LDL levels, we used the 
National Cholesterol Education Program Adult Treatment 
Panel III (ATP III) guidelines, which provide thresholds 
for diagnosing and targets for lowering high LDL choles-
terol on the basis of individual CHD risk (5,14). Findings 
on variation in LDL cholesterol levels in this population 
may be useful for researchers and policy makers in other 
urban environments.
Methods
NYC HANES is a population-based, cross-sectional, 
examination survey of noninstitutionalized New York City 
adult residents aged 20 years or older. A 3-stage cluster 
sampling design was used to recruit participants from 
June through December 2004. Detailed study methods 
are published elsewhere (15). The survey consisted of 
personal interviews, physical examinations, and labora-
tory testing. All survey instruments, protocols, and mea-
surements were standardized to National Health and 
Nutrition Examination Survey (NHANES) specifications. 
Lipid profiles were analyzed at the Lipoprotein Analytical 
Laboratory at Johns Hopkins University Hospital. Most 
laboratories that perform testing for NHANES were used 
for NYC HANES (16).
The NYC HANES protocol was approved by the New 
York City Department of Health and Mental Hygiene 
and the New York State Department of Health institu-
tional review boards. Study participants provided written, 
informed consent.
A total of 3,047 eligible participants were identified (84% 
household contact rate); 1,999 completed the face-to-face 
interview and at least 1 examination measurement (66% 
participant response rate), yielding an overall response 
rate of 55%. Of the 1,999 participants, valid high-density 
lipoprotein (HDL) and total cholesterol measurements 
were obtained for 1,783 participants. A random sample of 
participants (80%) was assigned to fast for at least 8 hours 
before giving blood, and of these, valid measurements 
were available for 1,150 participants. An additional 136 
participants not assigned to fast but who did voluntarily 
were similar to those assigned to fast for all demographic 
characteristics except age and were included in the sam-
ple. Valid LDL cholesterol data were available for 1,286 
participants.
ATP III risk groups
Participants were categorized into 1 of 4 CHD risk 
groups — high, moderately high, moderate, or low — fol-
lowing ATP III guidelines (14). These consider 1) presence 
of CHD or CHD risk equivalents, 2) presence of CHD risk 
factors, and 3) 10-year CHD risk using Framingham risk 
scoring (Table 1).
CHD and CHD risk equivalents were self-reported his-
tory of congestive heart failure, coronary heart disease, 
angina pectoris, myocardial infarction, stroke, or diabetes 
(determined by self-report or having a fasting glucose 
value ≥126 mg/dL). CHD risk factors were self-reported 
cigarette smoking, hypertension (measured blood pressure 
≥140/90 mm Hg or self-reported current use of antihy-
pertensive medications) (11), measured HDL cholesterol 
<40 mg/dL, family history of premature CHD (reported 
knowledge of heart attack or angina before age 50 among 
biological grandparents, parents, or siblings), and older 
age (men ≥45 y, women ≥55 y). Measured HDL cholesterol 
≥60 mg/dL was considered protective and offset the pres-
ence of 1 risk factor. The Framingham risk score estimates 
risk of developing angina pectoris, myocardial infarction, 
or CHD death within 10 years (17) and was calculated for 
each participant by using algorithms provided in ATP III 
guidelines.
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Cholesterol levels
Serum total and HDL cholesterol concentration were 
measured directly (12). LDL cholesterol was calculated 
from the fasting subsample’s sera by using the Friedewald 
equation (18):
LDL cholesterol [mg/dL] = total cholesterol [mg/dL] – HDL 
[mg/dL] – triglycerides [mg/dL]/5.
High LDL cholesterol was defined as currently taking 
cholesterol-lowering medications or having LDL choles-
terol levels at or greater than the ATP III risk-specific 
thresholds recommended for initiation of drug therapy in 
each risk group (5) (Table 1).
Awareness, treatment, and control of high LDL cholesterol
Participants were asked if they had ever had their 
cholesterol checked, and if so, whether a doctor or other 
health professional had told them their cholesterol level 
was high. Those who answered yes were considered aware 
of their diagnosis of high cholesterol and then asked 
the following questions about treatment: “To lower your 
blood cholesterol, have you ever been told by a doctor or 
other health professional to: a) eat fewer high-fat or high-
cholesterol foods, b) control your weight or lose weight, 
c) increase your physical activity or exercise, or d) take 
prescribed medicine?” Respondents who answered yes to 
any of the questions were asked whether they were follow-
ing this advice. Those who reported following at least 1 of 
these recommendations were classified as having adopted 
a healthier behavior to lower their cholesterol. Those who 
said they were taking prescribed cholesterol-lowering 
medications were classified as treated with medication. 
For all participants with high LDL cholesterol, control was 
defined as measured LDL cholesterol lower than the ATP 
III goal for their specific risk group (Table 1).
Demographics and health characteristics
NYC HANES assessed basic demographic characteris-
tics (age, sex, race/ethnicity, place of birth, income, and 
education), health insurance status, cigarette smoking, 
and physical activity. We used the NHANES definition of 
“US-born,” which includes the 50 states and Washington, 
DC; participants born in Puerto Rico and other US terri-
tories were categorized as foreign-born. “Vigorous physical 
activity” was based on Healthy People 2010 guidelines and 
defined as activity that causes heavy sweating or increases 
in breathing or heart rate for at least 20 minutes, at least 
3 days per week. Body mass index (BMI) was calculated 
from weight and height measurements.
Data analyses
We compared age-standardized New York City with 
national mean total and LDL cholesterol using the 
NHANES 2003-2004 fasting sample aged 20 years or older 
(16). We also compared the distribution of adults across 
various categories of total and LDL cholesterol levels.
We assigned each participant to a CHD risk group based 
on ATP III criteria and then estimated age-standardized 
prevalence of high LDL cholesterol among New York City 
adults overall and by ATP III risk group. To identify New 
York City populations at increased risk for high LDL cho-
lesterol, we estimated age-standardized prevalence of high 
LDL cholesterol by demographic and health characteris-
tics, including BMI, physical activity, smoking status, and 
other indicators of CHD risk.
We estimated awareness among adults with high LDL 
cholesterol, treatment and control among adults aware 
of their condition, and control among those treated with 
cholesterol-lowering medication. Awareness, treatment, 
and control of high LDL cholesterol were also examined by 
sociodemographic characteristics, insurance status, and 
ATP III risk group.
All statistical analyses were conducted by using 
SUDAAN version 10.0 (RTI International, Research 
Triangle Park, North Carolina) to account for complex 
survey design. Prevalence estimates were age-adjusted 
to the 2000 US standard population (19). Significance of 
univariate differences in prevalence, awareness, treat-
ment, and control of high LDL was determined by using 
t tests derived from the general linear contrast proce-
dure. We used χ2 tests to identify significant associations 
between the outcomes and covariates with 3 or more lev-
els. Relative standard errors and 95% confidence intervals 
(CIs) were calculated for percentages. Analytic weights 
were poststratified to represent the New York City adult 
population for NYC HANES data and the US adult popu-
lation for NHANES data, then further adjusted for age, 
sex, and race/ethnicity to address component and item 
nonresponse (20). Significance was set at P < .05.
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Results
Mean total and LDL cholesterol
Mean total cholesterol was significantly lower in New 
York City (197.7 mg/dL) than in the United States overall 
(203.0 mg/dL) (Table 2). No difference was seen in mean 
LDL cholesterol overall, but New York City foreign-born 
adults had higher mean LDL cholesterol than US foreign-
born adults (122.5 vs 117.8). 
Prevalence of ATP-defined high LDL cholesterol
Most New York City adults (64.8%; 95% CI, 61.4%-68.1%) 
were in the low ATP III risk group, while 17.9% (95% 
CI, 15.2%-20.9%) were in the high-risk group (Figure). 
According to ATP III-defined thresholds, total prevalence 
of high LDL cholesterol was 27.8% (Figure).
 
Figure. Age-standardized prevalence of high LDL cholesterol among New 
York City adults by ATP III risk category (5,1), New York City Health and 
Nutrition Examination Survey 200. High LDL cholesterol defined as cur-
rently taking cholesterol-lowering medications or having LDL cholesterol 
levels at or greater than the ATP III risk-specific thresholds recommended for 
initiation of drug therapy: ≥100 mg/dL for the high-risk group, ≥130 mg/dL 
for the moderately high-risk group, ≥160 mg/dL for the moderate-risk group, 
and ≥190 mg/dL for the low-risk group. Abbreviations: NYC, New York City; 
ATP III, National Cholesterol Education Program Adult Treatment Panel IIIs; 
LDL, low-density lipoprotein.
Significant differences in the prevalence of high LDL 
cholesterol were observed by ATP III risk group and across 
several demographic and health characteristics (Table 
3). There was a strong, graded association between ATP 
III risk group and the presence of high LDL cholesterol: 
11.1% of those at low risk, 31.3% of those at moderate risk, 
56.9% of those at moderately high risk, and 78.4% of those 
at high risk. Older age was associated with increased risk 
of high LDL cholesterol; more adults aged 60 years or older 
(58.6%) had high LDL cholesterol than did adults aged 40 
to 59 years (31.4%) and aged 20 to 39 years (6.6%). LDL 
cholesterol levels were higher among men than among 
women and among adults with high school education or 
less than among those with more education. A particularly 
low proportion of uninsured adults had high LDL choles-
terol (15.4%).
More overweight (29.6%) and obese (38.9%) participants 
had high LDL cholesterol than did those with normal or 
underweight BMI (17.6%), and more current smokers had 
high LDL cholesterol than nonsmokers (37.2% vs 24.8%). 
More adults with hypertension (41.3%) or diabetes (79.1%) 
had high LDL cholesterol than did those without these 
conditions (22.4% and 22.1%, respectively).
Awareness, treatment, and control of high LDL cholesterol
Among New York City adults with high LDL cholesterol, 
more than two-thirds (70.9%) were aware of their condi-
tion (Table 4). Rates of awareness varied significantly by 
age group, education, and health insurance status. Fewer 
adults aged 20 to 39 years (48.4%) and aged 40 to 59 
years (65.7%) were aware of their high LDL cholesterol 
than those aged 60 or older (80.4%). Fewer adults with 
high school education or less (64.0%) were aware of their 
condition than those with more education (80.8%). Three-
fourths (73.8%) of insured adults with high LDL choles-
terol were aware of their condition, compared with 46.2% 
of the uninsured (P = .005).
Among adults who were aware of their high LDL cho-
lesterol, most (88.1%) reported changing their diet, trying 
to lose weight, or increasing physical activity to lower cho-
lesterol. A lower proportion of younger people than older 
people (68.0% vs 92.0%) and a higher proportion of women 
than men (93.4% vs 83.8%) adopted healthier behaviors. 
Fewer aware adults in the high-risk group were treated 
with medication than those in the low-risk group (62.0% 
vs 77.1%). Aware adults aged 60 or older (72.8%) had 
higher rates of treatment with medication than those aged 
40 to 59 years (57.1%) and 20 to 39 years (35.7%). Only 
43.7% had their LDL cholesterol adequately controlled 
(Table 5). We observed significant disparities in rates of 
control among those who were aware of their condition by 
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risk group, age, and race/ethnicity. More than two-thirds 
(71.3%) of adults in the low-risk group had their LDL cho-
lesterol controlled, compared with only one-third of adults 
in the high-risk group. A smaller proportion of younger 
adults who were aware of their high cholesterol (22.4%) 
had their LDL cholesterol controlled than did those aged 
60 or older (51.3%). Rates of control among whites (53.2%) 
were higher than among blacks (31.2%) and Hispanics 
(31.8%).
Among those treated with cholesterol-lowering medica-
tion, two-thirds (68.3%; 95% CI, 56.9%-77.7%) had LDL 
cholesterol at recommended levels for their risk group. 
Fewer adults treated with medication in the high-risk 
group had their condition under control than did those 
in the low-risk group (53.8% vs 92.5%; P < .001), as were 
treated foreign-born adults compared with treated US-
born adults (57.8% vs 78.0%, P = .04).
Discussion
This study documents the large burden of high LDL 
cholesterol in New York City. We found that more than 1 
in 4 New York City adults have high LDL cholesterol, plac-
ing them at elevated risk for CHD (2,3). This proportion is 
similar to national levels (8).
We also found that nearly one-third of New York City 
adults with high LDL cholesterol were unaware of their 
condition. Among those who were aware, less than two-
thirds were taking cholesterol-lowering medications and 
less than half had their LDL cholesterol under control, 
suggesting that adults in New York City are not adequate-
ly treated. We found particularly low levels of treatment 
and control among those in the highest CHD risk groups, 
and low levels of control among black and Hispanic popu-
lations. Intensive efforts are needed to reduce LDL choles-
terol among these groups (4).
Lower awareness and treatment rates may be due in 
part to providers’ use of guidelines other than the 2004 
ATP III. Providers who use the US Preventive Services 
Task Force (USPSTF) guidelines would not screen low-
risk men before age 35 or women before age 45 (21). ATP 
III recommends screening all adults from age 20, every 5 
years. Using USPSTF guidelines, 16% of those we defined 
as unaware of high LDL cholesterol would not have been 
routinely screened. Similarly, low rates of treatment in the 
high-risk group may be due to limited provider adoption of 
the 2004 ATP III guidelines, which reduced the threshold 
for drug therapy in the high-risk group from ≥130 mg/dL 
to ≥100 mg/dL. However, using the former threshold of 130 
mg/dL for the high-risk group results in a similarly low 
treatment rate of 69.0% among those who were aware of 
having high LDL cholesterol.
Our analysis of the distribution of mean LDL choles-
terol found similar levels between New York City and the 
United States, but a higher mean LDL cholesterol among 
foreign-born adults in New York City than among foreign-
born adults in the United States overall. Foreign-born 
adults make up more than one-third (36.7%) of New York 
City’s population (compared with 12.5% of the US popula-
tion) (22). The higher mean in New York City may be due 
to differences in the racial/ethnic diversity in the NYC 
HANES foreign-born population (22% white, 18% black, 
19% Asian, 39% Hispanic, and 2% “other”) compared with 
the NHANES foreign-born population (27% white, 7% 
black, 28% Mexican American, 18% other Hispanic, and 
21% “other/multiracial”).
This study builds on previous NHANES studies by 
measuring LDL cholesterol among Hispanics and Asians, 
which could not be assessed in prior national surveillance 
data, and a closer examination of the foreign-born. New 
York City Hispanics had particularly low levels of aware-
ness compared with whites, possibly because of less access 
to care. Lack of insurance was associated with lower 
awareness levels. Diagnosis of high cholesterol requires 
a blood test, and treatment requires ongoing monitoring, 
costs of which can be barriers for people without insurance 
coverage. Also of concern is the disparity in control rates 
between foreign- and US-born adults who are treated with 
medication. These findings support the need to identify 
and respond to health disparities (23) to ensure increased 
access to health care for all groups.
The high prevalence of high LDL coupled with poor lev-
els of control suggests that effective strategies to reduce 
cholesterol requires a multilevel approach that includes 
and goes beyond the clinic. Population approaches to pre-
vent and reduce high LDL cholesterol offer opportunities 
to reduce risk across all risk groups (24).
Our findings are consistent with those of other studies 
that associated overweight or obesity and smoking with 
high LDL cholesterol (25,26) and underscore the need for 
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policies that improve the food environment and reduce 
smoking. New York City has introduced such population-
based initiatives. These include restricting the use of arti-
ficial trans fat in restaurants (27), increasing the number 
of mobile vendors that sell vegetables, and setting nutri-
tion standards for foods purchased by New York City 
agencies. Such policies aim to normalize heart-healthy 
eating and represent a promising strategy to reduce cho-
lesterol levels and CHD risk (24). Smoking prevalence is 
dramatically lower in New York City (28) after an increase 
in local and state cigarette taxes (making them among the 
most expensive in the country), hard-hitting antitobacco 
advertising, and wide distribution of free nicotine patches 
and gum (29). Federal action to extend similar and other 
effective policies across the country are needed for wide-
spread reductions in LDL cholesterol.
In addition to environment change approaches, improved 
clinical approaches to diagnosis and management of high 
LDL cholesterol are needed. Studies have demonstrated 
that delayed initiation of treatment for high LDL is com-
mon, despite evidence that early initiation and longer 
duration of therapy mitigates the atherosclerotic process 
(30). Once initiated, medication therapy is often not 
aggressive enough to reach targets because of providers’ 
concerns about adverse effects, tolerance, and patient 
adherence to specific medications (31). The introduction 
of panel management in primary care practices is an 
emerging proactive systematic approach to improve care, 
for example, by identifying a list of the provider’s patients 
with poorly controlled LDL for individualized outreach 
and follow-up by the health care team (32).
Limitations of the study include recall bias and measure-
ment error associated with self-report. The study strictly 
adhered to quality assurance procedures from NHANES 
to limit response bias. Poststratification weighting on 
the basis of age group, sex, race/ethnicity, and borough 
was applied to decrease the effect of component and item 
nonresponse. Additional analyses of treatment and control 
of LDL cholesterol within specific subgroups may have 
provided a deeper understanding of disparities but were 
limited by sample size.
An unacceptably large proportion of the New York City 
population has high or uncontrolled LDL cholesterol. New 
York City adults who are at the greatest risk for CHD 
need aggressive medical intervention to reduce their LDL 
cholesterol levels. On a broader level, programs that 
address primary prevention of high cholesterol through 
changes in the food environment and tobacco policies can 
prevent CHD-related illness and death and reduce health 
disparities.
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Tables
Table 1. National Cholesterol Education Program ATP III Guidelines for Risk Groups
ATP III Risk Group
LDL Cholesterol 
Goal, mg/dL
LDL Cholesterol Level 
for Initiation 
of Therapeutic Lifestyle 
Changes, mg/dL
LDL Cholesterol Level for 
Consideration of Drug Therapy, 
mg/dL
High risk: CHD or CHD risk equivalentsa (10-year riskb >20%) <100 ≥100 ≥100
Moderately high risk: ≥2 risk factorsc (10-year riskb 10%-20%) <130 ≥130 ≥130
Moderate risk: ≥2 risk factorsc (10-year riskb <10%) <130 ≥130 ≥160
Low risk: 0-1 risk factorc <160 ≥160 ≥190
 
Abbreviations: ATP III, Adult Treatment Panel III (5,1); LDL, low-density lipoprotein; CHD, coronary heart disease. 
a Self-reported history of congestive heart failure, coronary heart disease, angina pectoris, myocardial infarction, or stroke; self-reported history of or measured 
diabetes. 
b Framingham risk of developing angina pectoris, myocardial infarction, or CHD death (17); calculated by using ATP III algorithms. 
c Self-reported cigarette smoking, hypertension, measured high-density lipoprotein (HDL) cholesterol <0 mg/dL, family history of premature CHD, and older 
age. Measured HDL cholesterol ≥60 mg/dL offsets the presence of 1 risk factor.
VOLUME 7: NO. 3
MAY 2010
 www.cdc.gov/pcd/issues/2010/may/09_0196.htm • Centers for Disease Control and Prevention 9
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the 
Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and 
does not imply endorsement by any of the groups named above.
Table 2. Age-Standardized Mean Cholesterol Levels, NYC HANES 2004 Versus NHANES 2003-2004a
Characteristic
NYC HANES NHANES
P Valuecnb Mean, mg/dL (95% CI) nb Mean, mg/dL (95% CI)
Total cholesterol 
Overall 1,73 197.7 (195.7-199.7) ,76 203.0 (201.5-20.) <.001
Age, y
20-39 90 17.2 (1.-19.9) 1,552 19.5 (192.-196.7) <.001
0-59 660 206.3 (203.3-209.3) 1,273 209. (206.0-212.) .15
≥60 233 202.1 (196.5-207.7) 1,651 207.0 (20.6-209.) .11
Sex
Men 752 196.9 (19.2-199.7) 2,170 202.0 (200.-203.6) .002
Women 1,031 19.7 (195.9-201.5) 2,306 203. (200.-206.0) .01
Race/ethnicityd
Non-Hispanic white 522 199.1 (195.6-202.7) 2,17 203.7 (202.1-205.2) .02
Non-Hispanic black 35 195.2 (191.0-199.3) 71 19.5 (195.2-201.) .21
Asiane 225 200.1 (19.-205.9) NA NA NA
Hispanice 622 19.3 (195.1-201.) NA NA NA
Mexican Americanf NA NA 900 202. (199.-205) NA
Other Hispanicf NA NA 13 207. (19.0-217.6) NA
Place of birth
US-born 03 19. (191.6-197.2) 3,56 202.5 (200.9-20.1) <.001
Foreign-born (includes US territories) 97 200. (19.1-203.6) 929 205.3 (200.9-209.) .0
LDL cholesterol 
Overall 1,26 119. (117.7-121.9) 1,900 11.1 (115.7-120.5) .2
Age, y
20-39 63 111.0 (10.1-113.) 652 113.5 (110.1-116.9) .2
0-59 3 127.5 (123.7-131.2) 533 122.1 (117.1-127.0) .07
≥60 160 122.6 (116.6-12.5) 715 119.6 (116.3-123.0) .39
Sex
Men 53 122. (119.3-125.) 905 11.9 (115.6-122.2) .12
Women 7 11.1 (115.3-120.) 995 117.1 (11.1-120.2) .6
 
Abbreviations: NYC HANES, New York City Health and Nutrition Examination Survey; NHANES, National Health and Nutrition Examination Survey; CI, confidence 
interval; NA, not applicable; LDL, low-density lipoprotein. 
a All estimates age-adjusted to the 2000 US standard population. 
b Totals may differ because of nonresponse to specific questions. 
c Pairwise comparisons of New York City to US population based on general linear contrast procedure. 
d “Other race” not presented because of small numbers. 
e NHANES does not provide estimates for Hispanics or Asians. 
f NYC HANES does not provide estimates for Mexican Americans or “other Hispanics.”
(Continued on next page)
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Characteristic
NYC HANES NHANES
P Valuecnb Mean, mg/dL (95% CI) nb Mean, mg/dL (95% CI)
Race/ethnicityd
Non-Hispanic white 372 11.9 (115.2-122.7) 1,02 11.6 (116.0-121.2) .
Non-Hispanic black 21 11.5 (113.-123.2) 360 116.0 (111.-120.2) .2
Asiane 15 121.2 (113.6-12.) NA NA NA
Hispanice 5 121.9 (11.2-125.5) NA NA NA
Mexican Americanf NA NA 33 120.1 (116.9-123.) NA
Other Hispanicf NA NA 51 117.3 (105.0-129.6) NA
Place of birth
US-born 575 116. (113.6-120.1) 1,501 11.1 (115.3-120.9) .55
Foreign-born (includes US territories) 705 122.5 (119.-125.6) 399 117. (11.2-121.5) .06
 
Abbreviations: NYC HANES, New York City Health and Nutrition Examination Survey; NHANES, National Health and Nutrition Examination Survey; CI, confidence 
interval; NA, not applicable; LDL, low-density lipoprotein. 
a All estimates age-adjusted to the 2000 US standard population. 
b Totals may differ because of nonresponse to specific questions. 
c Pairwise comparisons of New York City to US population based on general linear contrast procedure. 
d “Other race” not presented because of small numbers. 
e NHANES does not provide estimates for Hispanics or Asians. 
f NYC HANES does not provide estimates for Mexican Americans or “other Hispanics.”
Table 3. Age-Standardized Prevalence of ATP III-Defined High LDL Cholesterol, NYC HANES 2004a
Characteristic nb % (95% CI) P Valuec
Total 1,271 27. (25.1-30.) NA
ATP III risk group <.001
High risk 17 7. (69.3-5.) <.001
Moderately high risk 65 56.9 (32.6-7.3) .001
Moderate risk 135 31.3 (22.-1.3) <.001
Low risk 97 11.1 (7.9-15.3) Reference
 
Abbreviations: ATP III, Adult Treatment Panel III (5,1); LDL, low-density lipoprotein; NYC HANES, New York City Health and Nutrition Examination Survey; CI, 
confidence interval; NA, not applicable. 
a High LDL cholesterol defined as currently taking cholesterol-lowering medications or having LDL cholesterol levels at or greater than the ATP III risk-specific 
cutpoints recommended for initiation of drug therapy. All estimates age-adjusted to the 2000 US standard population. 
b Totals may differ because of nonresponse to specific questions. 
c χ2 test of independence computed for variables with 3 or more levels. Pairwise comparisons to reference group based on general linear contrast procedure. 
d “Other race” not presented because of small numbers.
Table 2. (continued) Age-Standardized Mean Cholesterol Levels, NYC HANES 2004 Versus NHANES 2003-2004a
(Continued on next page)
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Characteristic nb % (95% CI) P Valuec
Age, y <.001
20-39 636 6.6 (.7-9.1) <.001
0-59 77 31. (26.6-36.6) <.001
≥60 15 5.6 (50.2-66.5) Reference
Sex
Men 533 3.5 (30.-3.) Reference
Women 73 22. (19.2-25.9) <.001
Race/ethnicityd .0
Non-Hispanic white 370 2.1 (23.-32.9) Reference
Non-Hispanic black 276 2.7 (22.9-35.2) .9
Non-Hispanic Asian 157 29.6 (21.1-39.) .7
Hispanic 51 25.3 (21.1-30.1) .3
Place of birth
US-born 56 27.5 (23.6-31.9) Reference
Foreign-born (includes US territories) 702 27.7 (23.9-31.9) .95
Annual household income, $
<20,000 2 29.2 (2.5-3.) .7
≥20,000 2 26.9 (23.5-30.6) Reference
Education
High school or less 620 32.9 (29.1-36.9) .001
More than high school 69 23. (19.6-27.7) Reference
Health insurance status
Insured 937 29. (26.-33.0) Reference
Uninsured 331 15. (10.0-23.0) <.001
Body mass index, kg/m2 <.001
Normal/underweight (<25.0) 509 17.6 (13.7-22.2) Reference
Overweight (25.0-29.9) 36 29.6 (25.1-3.5) <.001
Obese (≥30.0) 32 3.9 (3.1-.0) <.001
 
Abbreviations: ATP III, Adult Treatment Panel III (5,1); LDL, low-density lipoprotein; NYC HANES, New York City Health and Nutrition Examination Survey; CI, 
confidence interval; NA, not applicable. 
a High LDL cholesterol defined as currently taking cholesterol-lowering medications or having LDL cholesterol levels at or greater than the ATP III risk-specific 
cutpoints recommended for initiation of drug therapy. All estimates age-adjusted to the 2000 US standard population. 
b Totals may differ because of nonresponse to specific questions. 
c χ2 test of independence computed for variables with 3 or more levels. Pairwise comparisons to reference group based on general linear contrast procedure. 
d “Other race” not presented because of small numbers.
Table 3. (continued) Age-Standardized Prevalence of ATP III-Defined High LDL Cholesterol, NYC HANES 2004a
(Continued on next page)
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Characteristic nb % (95% CI) P Valuec
Vigorous physical activity
≥20 min, 3 d/week 322 26. (20.-33.9) .6
<20 min, 3 d/week 96 2. (25.2-31.7) Reference
Smoking
Current smoker (last 30 days) 313 37.2 (31.7-3.2) <.001
Nonsmoker 957 2. (21.-2.1) Reference
Diabetes
Has diabetes 120 79.1 (67.9-7.2) <.001
No diabetes 1,150 22.1 (19.3-25.2) Reference
Hypertension
Has hypertension 227 1.3 (3.1-.9) <.001
No hypertension 1,02 22. (1.9-26.3) Reference
 
Abbreviations: ATP III, Adult Treatment Panel III (5,1); LDL, low-density lipoprotein; NYC HANES, New York City Health and Nutrition Examination Survey; CI, 
confidence interval; NA, not applicable. 
a High LDL cholesterol defined as currently taking cholesterol-lowering medications or having LDL cholesterol levels at or greater than the ATP III risk-specific 
cutpoints recommended for initiation of drug therapy. All estimates age-adjusted to the 2000 US standard population. 
b Totals may differ because of nonresponse to specific questions. 
c χ2 test of independence computed for variables with 3 or more levels. Pairwise comparisons to reference group based on general linear contrast procedure. 
d “Other race” not presented because of small numbers.
Table 4. Awareness of High LDL Cholesterol, NYC HANES 2004
Characteristic na % (95% CI) P Valueb
Total 269 70.9 (6.2-76.7) NA
ATP III risk group .06
High risk 11 66. (57.7-7.) .09
Moderately high risk 0 63.1c (6.-77.2) .10
Moderate risk 37 3.7c (67.1-92.9) .6
Low risk 51 79. (6.5-9.5) Reference
 
Abbreviations: LDL, low-density lipoprotein; NYC HANES, New York City Health and Nutrition Examination Survey; CI, confidence interval; NA, not applicable; ATP 
III, Adult Treatment Panel III (5,1). 
a Totals may differ because of nonresponse to specific questions. 
b χ2 test of independence computed for variables with 3 or more levels. Pairwise comparisons to reference group based on general linear contrast procedure. 
c Estimate should be interpreted with caution. Estimate’s relative standard error (a measure of estimate precision) is >30% or sample size is <50, making the 
estimate potentially unreliable. 
d “Other race” (n = 17) not presented because of small numbers.
Table 3. (continued) Age-Standardized Prevalence of ATP III-Defined High LDL Cholesterol, NYC HANES 2004a
(Continued on next page)
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Characteristic na % (95% CI) P Valueb
Age, y .009
20-39 36 .c (30.3-67.1) .003
0-59 16 65.7 (56.6-73.) .02
≥60 7 0. (69.7-.0) Reference
Sex
Men 15 67.6 (5.5-75.5) Reference
Women 12 75.5 (66.5-2.7) .15
Race/ethnicityd .30
Non-Hispanic white 91 7.1 (66.1-6.) Reference
Non-Hispanic black 62 67.2 (5.-77.) .17
Non-Hispanic Asian 33 65.2c (.7-7.) .1
Hispanic 2 63.2 (51.3-73.7) .0
Place of birth
US-born 113 73.7 (63.-1.9) Reference
Foreign-born (includes US territories) 155 6.3 (59.7-75.) .3
Education
High school or less 166 6.0 (5.9-72.1) .006
More than high school 102 0. (71.-7.5) Reference
Annual household income, $
<20,000 100 65.6 (5.5-75.2) .26
≥20,000 161 72. (65.1-79.5) Reference
 
Abbreviations: LDL, low-density lipoprotein; NYC HANES, New York City Health and Nutrition Examination Survey; CI, confidence interval; NA, not applicable; ATP 
III, Adult Treatment Panel III (5,1). 
a Totals may differ because of nonresponse to specific questions. 
b χ2 test of independence computed for variables with 3 or more levels. Pairwise comparisons to reference group based on general linear contrast procedure. 
c Estimate should be interpreted with caution. Estimate’s relative standard error (a measure of estimate precision) is >30% or sample size is <50, making the 
estimate potentially unreliable. 
d “Other race” (n = 17) not presented because of small numbers.
Table 4. (continued) Awareness of High LDL Cholesterol, NYC HANES 2004
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Table 5. Treatment and Control of High LDL Cholesterol Among Respondents Aware of Their Status, NYC HANES 2004
Characteristic na
Adopted Healthier 
Behavior 
% (95% CI) P Valueb
Treated With 
Medication 
% (95% CI) P Valueb
Controlledc 
% (95% CI) P Valueb
Total 10 .1 (2.3-92.2) NA 6.0 (55.-71.) NA 3.7 (3.-53.5) NA
ATP III risk group .0 — .17 — .03
High risk  93.9 (6.7-97.3) .17 62.0 (9.5-73.1) .12 33.3 (22.0-7.0) .001
Moderately high risk 21 3.5d (60.6-9.) .6 6.2d (23.-70.) .0 3.9d (17.-65.7) .0
Moderate risk 31 75.d (55.-.6) .35 66.7d (5.3-2.9) .39 2.1d (2.7-61.7) .03
Low risk 0 5.d (70.7-93.) Reference 77.1d (60.2-.3) Reference 71.3d (51.0-5.6) Reference
Age, y .16 — .05 — .07
20-39 1 6.0d (1.2-6.6) .06 35.7d (16.0-61.) .009 22.d (.2-.) .02
0-59 9 6. (76.7-92.) .26 57.1 (5.0-6.3) .0 37.2 (27.3-.2) .11
≥60 6 92.0 (3.3-96.) Reference 72. (5.9-3.) Reference 51.3 (37.3-65.1) Reference
Sex
Men 9 3. (7.2-90.3) Reference 6.3 (52.-7.) Reference 6.7 (3.2-59.6) Reference
Women 91 93. (5.9-97.0) .09 63.6 (51.6-7.1) .93 39.9 (29.-51.6) .39
Race/ethnicitye .2 — .11 — .1
Non-Hispanic white 70 9.3 (0.-9.) Reference 67.2 (53.-7.2) Reference 53.2 (39.9-66.0) Reference
Non-Hispanic black 0 5.7d (69.3-9.1) .62 56.1d (3.2-72.5) .32 31.2d (16.-51.1) .07
Non-Hispanic Asian 20 96.d (77.1-99.5) .13 3.6d (63.-93.7) .0 7.5d (25.7-70.3) .65
Hispanic 50 3.7 (69.0-92.2) .2 55.5 (1.5-6.7) .22 31. (19.2-7.7) .03
Place of birth
US-born 0 .0 (79.-93.3) Reference 6.5 (50.5-76.) Reference 50.3 (36.5-6.1) Reference
Foreign-born (includes US ter-
ritories)
100 .2 (79.2-93.6) .97 63.5 (53.0-72.) .91 36.7 (26.6-.1) .12
Education
High school or less 102 .3 (75.0-90.6) .11 63.0 (51.3-73.3) .77 39.7 (2.9-51.6) .27
More than high school 7 92.3 (.1-96.) Reference 65.1 (53.-75.3) Reference .1 (35.7-60.) Reference
Annual household income, $
<20,000 62 93. (5.0-97.2) .05 67.3 (52.5-79.3) .37 5.3 (32.0-59.2) .5
≥20,000 112 . (76.1-90.2) Reference 59.3 (.1-69.7) Reference 39.7 (2.-52.3) Reference
 
Abbreviations: LDL, low-density lipoprotein; NYC HANES, New York City Health and Nutrition Examination Survey; CI, confidence interval; NA, not applicable; ATP 
III, Adult Treatment Panel III (5,1). 
a Totals may differ because of nonresponse to specific questions. 
b χ2 test of independence computed for variables with 3 or more levels. Pairwise comparisons to reference group based on general linear contrast procedure. 
c “Controlled” is defined as <100 mg/dL for the high risk group, <130 mg/dL for the moderately high risk group, <130 mg/dL for the moderate risk group, and 
<160 mg/dL for the low risk group. 
d Estimate should be interpreted with caution. Estimate’s relative standard error (a measure of estimate precision) is >30% or sample size is <50, making the 
estimate potentially unreliable. 
e “Other race” (n = 17) not presented because of small numbers.
